MEDI9447, a human monoclonal antibody specific to CD73, increased the infiltration of effector CD8+T cells and macrophages in mouse models, alleviated adenosine-mediated lymphocyte inhibition in vitro, and inhibited isogenic tumor growth in mice (43). This evidence concerns the gene CD8A and neoplasm.